Data / Federal rules / 2024-18087
Schedules of Controlled Substances: Placement of Zuranolone in Schedule IV
The Drug Enforcement Administration published this final rule in the Federal Register on August 14, 2024. It took effect on September 13, 2024.
SpecStream is the live web data engine for teams and agents. It reads every rule and proposed rule in the Federal Register each morning, and this page is that reading. Name your industry once and new rules, comment deadlines and effective dates arrive in your sheet, CRM, Slack or agent as they are published.
What the agency says
This final rule adopts, without change, an interim final rule with request for comments published in the Federal Register on October 31, 2023, placing zuranolone (chemically known as 1-[2- [(3R,5R,8R,9R,10S,13S,14S,17S)-3-hydroxy-3,13-dimethyl- 2,4,5,6,7,8,9,10,11,12,14,15,16,17-tetradecahydro-1H- cyclopenta[a]phenanthren-17-yl]-2-oxoethyl]pyrazole-4-carbonitrile) and its salts in schedule IV of the Controlled Substances Act. With the issuance of this final rule, the Drug Enforcement Administration maintains zuranolone, including its salts, in schedule IV of the Controlled Substances Act.
Key facts
- Document number
- 2024-18087
- Type
- Final rule
- Action
- Final rule
- Agency
- Justice Department; Drug Enforcement Administration
- Published
- August 14, 2024
- Takes effect
- September 13, 2024
- Dates
- Effective September 13, 2024.
- Docket
- Docket No. DEA1258
- Code of Federal Regulations
- 21 CFR 1308
- Topics
- Administrative practice and procedure; Drug traffic control; Reporting and recordkeeping requirements
- Pages
- 3
Other documents from the Drug Enforcement Administration
Everything from the Drug Enforcement Administration · Rules on administrative practice and procedure · Rules on drug traffic control · Rules on reporting and recordkeeping requirements · Published in August 2024
Read from the Federal Register API, last updated 2026-10-23. The document on federalregister.gov is the official record; dates and dockets can change through later corrections. Free to reuse with credit to SpecStream under CC BY 4.0.